The salvage therapy utilizing human umbilical cord-derived mesenchymal stem cells for the treatment of critically ill patients with COVID-19
According to our findings, intravenous infusion of hUC-MSCs has proven to be safe, and it has also proven to show potential therapeutic benefits for patients with severe COVID-19.
Authors
- Yingan Jiang (ORCID: https://orcid.org/0000-0003-4912-7494)
- Haibo Dong
- Boran Li
- Qiao-Yu Yuan
- Yun Zhang (ORCID: https://orcid.org/0000-0001-9621-1408)
- Qi Qi (ORCID: https://orcid.org/0000-0003-3191-0544)
- Yu Zhang (ORCID: https://orcid.org/0000-0002-7384-0778)
- Wenjie Wu (ORCID: https://orcid.org/0000-0001-5888-1208)
- Weiqi Yao (ORCID: https://orcid.org/0000-0002-1352-6285)
- Ruizhen Hou
Institutions
- Wuhan University of Technology (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Heritage Preservation (US)
- Wuhan University (CN)
- Yangtze Optical Electronic (China) (CN)
- Cell Technology (China) (HK)
- Renmin Hospital of Wuhan University (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Hubei University of Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1594373
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China
- Project 211